Use of Rituximab as an off-Label medication in Glomerular Diseases: Clinical Perspective

Conclusion: Our data support RTX use in resistant MCD and MN. RTX showed success in LN and IgG4 related disease, but not FSGS or C3GN. The small vasculitis cases number does not allow drawing a conclusion on RTX effectiveness.
Source: Medical Principles and Practice - Category: Internal Medicine Source Type: research